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Selectivity of Binding To Estrogen Receptors Alpha and Beta As Deter-
mined by Fluorescence Polarization
Catherine T. Knuff, Hannah M. Varner, Patricia B. O’Hara.
Amherst College, Amherst, MA, USA.
Estrogen’s role in cell growth and proliferation has long been appreciated both
in the normal development of secondary sexual characteristics and in diseased
states in cancers of the breast, ovaries and uterus. We are beginning to appre-
ciate estrogen’s expanded role in maintaining such diverse functions as the
skin’s elasticity, the health of the central nervous system, bone density and
cardiac health. Estrogen plays out its roles in varied tissues by binding to
two major ligand activated nuclear receptors, estrogen receptor alpha (ER-a)
and estrogen receptor beta (ER-b). The interrelationship of the two receptors
plays a role in the responsiveness of certain breast cancers to drug treatment.
Though the ligand binding sites of the two receptors differ by only two amino
acids, the overall degree of homology between ER-a and ER-b is low. The
body uses the receptor selectivity to its advantage by dispersing the receptors
in varying ratios to different tissues. Of these actions ER-a is thought to be re-
sponsible for the majority with ER-b playing a minor role in all and having
more significance in the cardiovascular and skeletal systems. Small molecules
have been identified which bind to one or the other receptors with differing
binding affinities. These selective estrogen receptor modulators (SERMs) hold
the potential to be pharmacologically effective in treating diseases specific
to one type of estrogen receptor while not affecting the other. For example,
ER-a and ER-b are both present in breast tissue, and the ratio of beta to alpha
is being examined as one indicator in determining the likelihood of successful
treatment of breast cancer by certain drugs. Here we use changes in the fluo-
rescence polarization to calculate binding affinities for each of several small
molecules to ER-a and ER-b.
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The NMDA family of ionotropic glutamate receptors are ligand-gated ion
channels that mediate the majority excitatory synaptic transmission in the
brain. Dysfunction of NMDA receptor signalling is involved in a range of neu-
rological and psychiatric diseases for which NMDA receptors are considered
important drug targets. NMDA receptors are tetrameric assemblies comprised
of two glycine-binding GluN1 subunits and two glutamate-binding GluN2 sub-
units. Four different GluN2 subunits (GluN2A-D) exist with distinct expression
and functional profiles. Identification of subunit-selective NMDA receptor ag-
onists, antagonists, or modulators could prove to be both valuable pharmaco-
logical tools as well as potential new therapeutic agents.
Polyamine toxins are a group of small molecules found in spiders and wasps
that are open-channel blockers of NMDA receptors. Polyamine toxins have
found valuable use as pharmacological tools based on their high affinity and
selectivity, but have not yet been explored as templates for the development
of NMDA receptor drugs. Argiotoxin-636 (ArgTX-636) is a polyamine toxin
isolated from the venom of the orb weaver spider Argiope lobata. ArgTX-
636 is among the most potent inhibitors of NMDA receptors and blocks these
in a use- and voltage-dependent manner, presumably by binding to the ion
channel region. We have recently shown that modifications within the poly-
amine tail of ArgTX-636 can control subtype selectivity. In this study, we
explore the rational design of ArgTX-636 analogs to produce NMDA receptor
inhibitors with marked improvement in subtype selectivity. Systematic varia-
tion of the polyamine tail lead to identification of ArgTX analogs with pro-
nounced subtype selectivity, such as 100-fold differential potency between
GluN2A, GluN2B, or GluN2C versus GluN2D containing receptors. To study
the structural basis for NMDA subtype selectivity, compounds were docked
into models of the NMDA receptor ion channels.
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A Survey for Small Multidrug Resistance Protein Multimerization in the
Presence of Ligand Using Sds-Page Analysis
Denice C. Bay, Raymond J. Turner.
University of Calgary, Calgary, AB, Canada.
EmrE and SugE are members of the small multidrug resistance protein family
that can efflux quaternary cation compounds (QCC) via proton motive force
within the Escherichia coli plasma membrane. Members of this integral mem-
brane protein family are characterized by their short (~100-140 amino acids)
four transmembrane (TM) alpha- helix conformation and highly conservedglutamate residue within the active site. EmrE protein can confer broad mul-
tidrug resistance to the host strain unlike SugE protein, which demonstrates
limited multidrug resistance. The exact multimeric state or states of both pro-
teins during transport and ligand binding is not well understood and often
yield conflicting results that are specific to the conditions of study. To explore
SMR multimerization as influenced by QCC ligands, organic solvent extracted
EmrE and SugE protein from E. coli membranes were characterized in the de-
tergents, sodium dodecyl sulfate (SDS) and dodecyl maltoside (DDM) at
varying protein concentrations. SMR proteins solubilized in both detergents
demonstrated a predominately monomeric state but upon increasing particular
QCC ligand concentrations resulted in multimer formation or enhancement
using SDS- tricine polyacrylamide gel electrophoresis (PAGE). The results
from this PAGE based assay demonstrate that: i) SMR multimers are induced
by particular ligands that may relate to ligand shape and ii) only EmrE multi-
merization is induced by particular ligands, whereas SugE appears to be
insensitive to drug enhanced oligomerization. Therefore, SMR multimer
variability may be dependent upon the nature of the transported substrate
and SMR subclass; only EmrE can alter its subunit composition in response
to particular QCC substrates. This PAGE based assay provides the framework
to explore the influence of diverse QCC substrates for its affects on SMR
multimerization.
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Towards Identifying the Structural Basis For Inhibition By a Newly
Discovered Class of CLC Chloride-Channel Inhibitors
Andrew E. Howery, Jonas Almqvist, Justin Du Bois, Merritt Maduke.
Stanford University, Stanford, CA, USA.
CLC chloride channels and transporters play diverse physiological roles.
Small-molecule inhibitors of the CLCs would be powerful tools to understand
and potentially treat a variety of CLC-related human diseases. In addition to
their potential therapeutic benefits, inhibitors can be used to trap channels or
transporters in particular conformational states, potentially advancing our un-
derstanding of the structural basis for CLC activity. Despite their usefulness,
specific small molecule inhibitors for CLC proteins are scarce. To address
this shortfall, we have embarked on a search for novel inhibitors of the CLC
proteins. We have discovered a panel of small molecules active against both
the human ClC-K and the prokaryotic ClC-ec1 homologs. Because ClC-ec1
is amenable to structural studies by X-ray crystallography, co-crystallization
experiments with these novel inhibitors are in progress. As an alternative
method to identifying the inhibitor-binding site, we have synthesized photo-re-
active diazirine derivatives of the inhibitors and shown that these photo-affinity
reagents specifically inhibit ClC-ec1. Experiments to identify the binding site
using protease digestion coupled with mass spectrometry are currently under-
way. Once located, protein/inhibitor interactions gleaned from the labeling of
ClC-ec1 could allow us to rationally design more potent inhibitors of mamma-
lian transporters and channels.
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Structural Basis For the Allosteric Mechanism of Serine Protease
Inhibition By An Antibody
Rajkumar Ganesan.
Genentech Inc, South San Francisco, CA, USA.
The widespread use of antibody therapeutics and the emergence of proteases as
compelling disease targets contrast sharply with our poor understanding of how
antibodies achieve protease inhibition. Recent structural studies have outlined
the mechanism of serine protease inhibition by active site-directed antibodies.
However, the molecular basis of allosteric inhibition by antibodies has been
elusive. The present study, with three crystal structures and a comprehensive
kinetic analysis, now provides a detailed view of how an allosteric antibody in-
hibits protease activity. We determined the structure (2.35 A˚ resolution) of the
trypsin-like serine protease hepatocyte growth factor activator (HGFA) in com-
plex with the allosteric antibody Ab40, a competitive inhibitor of HGFA cata-
lytic activity. The antibody binds at the periphery of the substrate binding cleft
and imposes a conformational change on the entire 99-loop (chymotrypsinogen
numbering). Remarkably, a single residue deletion (Trp96H) of Ab40 abol-
ished inhibition of HGFA activity commensurate with the reversal of the
99-loop conformation to its ‘competent’ state as evidenced from the structure
of HGFA/ Fab40.DTrp96H resolved at 2.9 A˚. In order to understand the precise
mechanism by which Ab40 interferes with the proteolytic activity of HGFA, we
determined the structure of HGFA/Fab40.DTrp96H in complex with substrate-
mimicking peptidic inhibitor (Ac-KQLR-chloromethlyketone) at 2.7 A˚. Com-
parison of these three structures led us to propose a model wherein the binding
of Ab40 to HGFA and the concomitant change in the conformation of the
99-loop may result in the partial collapse of substrate binding subsite S2 and
the reorganization of subsite S4, leading to the inhibition of HGFA activity
36a Sunday, February 21, 2010by Ab40. Thus our results define a novel ‘allosteric switch’ mechanism as the
basis of protease inhibition by an allosteric antibody.
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Allosteric Mechanism in Neurophysin
Hunjoong Lee, Mandar Naik, Clay Bracken, Esther Breslow.
Weill Medical College of Cornell University, New York, NY, USA.
Neurophysins are small two- domain proteins that exhibit ligand-facilitated di-
merization and its reciprocal-stronger binding by dimer than by monomer. We
have previously reported evidence of conformational differences between un-
liganded monomer and dimer, but had not established their identity, their ori-
gin, or how they affect binding affinity.
In the present study we have determined the relative structures of a neurophysin
monomer and its dimer by NMR spectroscopy. The structures show that a num-
ber of neurophysin residues that interact with the essential tyrosine of the ligand
peptide move from locations in the unliganded monomer that are unfavorable
for binding to positions in the unliganded dimer that more closely resemble
those of the liganded state, thereby contributing to the stronger binding by di-
mer. We have also identified the origin of the dimerization-induced conforma-
tional change; i.e., the same residues that form the principal inter-domain bonds
in the monomer via side-chain interactions form the principal inter-subunit
bonds in the dimer via backbone hydrogen bonding. Steric crowding upon di-
merization leads to a modification of inter-domain interactions, a resultant
change in the relative orientation of the two domains and associated changes
in intra-domain interactions. The principal residues responsible for these inter-
actions are the Cys residues of the 28-34 disulfide bridge (amino domain) and
74-79 disulfide bridge (carboxyl domain). Strong inter-domain van der Waals
interactions between sulfur atoms appear to play important roles in determining
the relative domain orientation.
(Supported by grant GM-17528 from NIH).
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Lactose Binding To Galectin-1 Occurs With Negative Cooperativity and
Attenuates Internal Motions Throughout the Protein
Irina V. Nesmelova1, Elena Ermakova2, Vladimir A. Daragan3,
Mabel Pang4, Linda G. Baum4, Kevin H. Mayo3.
1UNCC, Charlotte, NC, USA, 2Kazan Institute of Biochemistry &
Biophysics, Kazan, Russian Federation, 3University of Minnesota,
Minneapolis, MN, USA, 4University of California, Los Angeles, CA, USA.
Galectins are a sub-family of lectins with a conserved carbohydrate recognition
domain (CRD) that interacts with beta-galactosides. By binding cell surface
glycoconjugates, galectin-1 is involved in cell adhesion and migration pro-
cesses and is an important regulator of tumor angiogenesis. Here, we used het-
eronuclear NMR spectroscopy and molecular modeling to investigate lactose
binding to galectin-1 and to derive solution NMR structures of galectin-1 in
the lactose bound and unbound states. Structure analysis shows that the beta-
strands and loops around the lactose binding site which are more open and
dynamic in the unbound state, fold in around the bound lactose molecule damp-
ening internal motions at that site. Analysis of titration binding data reveal that
lactose binds the two CRDs of the galectin-1 dimer with negative cooperativity.
Molecular dynamics simulations provide insight into structural dynamics of the
half-loaded lactose state and, together with NMR data, suggest that lactose
binding at one site transmits a signal through the beta-sandwich and loops to
the second binding site. Overall, our results provide new insight into galec-
tin-1 structure-function relationships and to protein-carbohydrate interactions
in general.
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Conformational Plasticity in IL-2 Is Captured Via in Silico Fragment-
Based Drug Design Using SILCS Fragmaps
Olgun Guvench.
University of New England, Portland, ME, USA.
The IL-2 protein is an experimentally well-characterized example of conforma-
tional plasticity in a protein-protein binding interface. Whereas the original
crystal structure of the IL-2 protein lacked a particular binding pocket at the
interface, subsequent structures of the protein complexed with small-molecule
inhibitors have shown the creation of a hydrophobic pocket in order to accom-
modate inhibitor binding poses. A new in silico fragment-based drug design
methodology (SILCS FragMaps) was applied to the original IL-2 crystal struc-
ture and has been found to recapitulate this pocket observed in the complexes.
Furthermore, the pocket is seen to have an affinity for hydrophobic fragments,
consistent with experimental inhibitor binding poses. As the SILCS FragMaps
methodology is based on explicit-water all-atom molecular dynamics simula-
tions, the methodology is able to capture both the conformational plasticity
in the IL-2 surface required for pocket formation as well as the selective parti-
tioning of small hydrophobic fragments into the pocket from bulk solution.192-Pos
Different Binding Modes of Compounds Affecting CETP Activity: Dalce-
trapib and Torcetrapib
Christine Magg, Cyrille Maugeais, Gregor Dernick, Walter Huber,
Elisabeth von der Mark, Georg Schmid, Ralf Thoma, Eric J. Niesor.
F. Hoffmann - La Roche Ltd., Basel, Switzerland.
Cholesteryl ester transfer protein (CETP) is a hydrophobic glycoprotein in
plasma and facilitates the exchange of neutral lipids between various lipo-
proteins resulting in a net transport of cholesteryl ester from HDL to LDL.
Decrease in CETP activity leads to an increase of HDL cholesterol which
potentially reduces cardiovascular risk.
Human recombinant CETP (rhCETP) was purified to homogeneity by hydro-
phobic interaction chromatography and size exclusion chromatography
(SEC). The protein showed an extraordinarily high thermodynamic stability
against thermal as well as denaturant-induced unfolding.
The effects of CETP on lipoprotein profiles were characterized after in-vitro
incubation of plasma with rhCETP followed by SEC and reverse phase pro-
tein arrays. Monitoring the distribution of apolipoproteins and the cholesterol
profiles confirmed the transfer of cholesteryl ester from HDL to LDL in-
duced by CETP. In the presence of the potent CETP inhibitor torcetrapib
(1 mM) added CETP is bound to lipoproteins while free CETP can still be
detected in presence of dalcetrapib (3 mM), a compound from a different
chemical class.
14C-torcetrapib and 14C-dalcetrapib were bound to CETP immobilized on se-
pharose and incubated with excess of unlabelled compounds. 14C-dalcetrapib
bound as Dalcetrapib-thiol could only be displaced in the presence of reducing
agent by an excess of unlabeled dalcetrapib but not by torcetrapib. Dalcetrapib
did not compete for binding of 14C-torcetrapib.
Interaction studies with Surface Plasmon Resonance confirmed reversible co-
valent binding of dalcetrapib-thiol and different binding sites for dalcetrapib
and torcetrapib. In agreement with literature cysteine 13 of CETP was identi-
fied as attachment point of dalcetrapib-thiol. All data suggested that torcetrapib
and dalcetrapib bind to different sites on CETP which may be related to differ-
ences observed in their pharmacological profiles.193-Pos
Cholesteryl Ester Transfer Protein Penetrates Lipoproteins For Choles-
teryl Ester Transfer
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Human cholesteryl ester transfer protein (CETP), a hydrophobic glycoprotein
(476 amino acids, ~74 kDa), mediates the transfer of cholesteryl ester (CE)
from high-density lipoproteins (HDL) to apo-B containing lipoproteins (low-
density lipoproteins - LDL; very low density lipoproteins - VLDL). The crystal
structure of CETP reveals a banana-shaped protein consisting of N- and C-ter-
minal b-barrel domains, a central b-sheet, and a ~60-A˚-long hydrophobic cav-
ity. Since CETP deficiency is associated with elevated ‘good-cholesterol’
(HDL-associated) levels via delayed catabolism, as a result, CETP has become
a high interest pharmacological drug target.
Here, we investigated the mechanism of CETP-mediated neutral lipid transfer
by electron microscopy (EM), image-processing, and molecular dynamic sim-
ulations (MDS). We discovered that: 1) CETP bridges HDL and LDL/VLDL to
form a ternary complex; 2) the CETP C-terminal beta-barrel domain penetrates
partially into the LDL/VLDL surface; 3) the N-terminal beta-barrel domain
penetrates through the HDL surface and interacts with the CE core; and 4)
MDS analysis suggested that the penetrating regions of CETP are highly mo-
bile and form pores that connect to cavities running through the central axis
of the CETP molecule to generate a tunnel. The tunnel was mainly hydrophobic
and connected the distal ends through its central cavities. Thus, we proposed
CETP resembles a Chinese finger trap, in which both beta-barrel domains pen-
etrate the lipoprotein surface, resulting in pressure from both ends. The pressure
may result in the anti-twisting of the two domains, leading to opening of the
tunnel for CE transfer between HDL and LDL. The distal end of N-terminal
beta-barrel domain could be particularly important for the design of pharmaco-
logical inhibitors, as blockage of the N-terminal beta-barrel domain would
prevent CE transfer with a low probability of off target effects on normal HDL
metabolism.
